Among all physiologic functions of nitric oxide (NO) known so far, NO-dependent regulation
of vascular tone is one of the most important. Under physiological conditions vascular NO is …

Background Recent studies have shown that sodium-glucose cotransporter-2 inhibitors
(SGLT2i) can achieve significant improvement in blood pressure in people with diabetes …

Hypertension is the most frequent chronic and non-communicable disease all over the
world, with about 1.5 billion affected individuals worldwide. Its impact is currently growing …

Metabolic diseases, such as diabetes, gout and hyperlipidemia are global health
challenges. Among them, diabetes has been extensively investigated. Type 2 diabetes …

(1) Background: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors constitute a novel
drug class with remarkable cardiovascular benefits for patients with chronic heart failure …

The management of type 2 diabetes (T2D) involves decreasing plasma glucose levels and
reducing cardiovascular and microvascular complications. Diabetic kidney disease (DKD) …

Sodium glucose transporter type 2 (SGLT2) molecules are found in proximal tubules of the
kidney, and perhaps in the brain or intestine, but rarely in any other tissue. However, their …

The profile of sphingomyelin and its metabolites shows changes in the plasma, organs, and
tissues of patients with cardiovascular, renal, and metabolic diseases. The objective of this …

Objective: To evaluate the efficacy and safety of ertugliflozin in patients with type 2 diabetes.
Methods: MEDLINE, EMBASE, and Cochrane Library were searched (July 31, 2021) for …

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) were originally developed as glucose-
lowering agents. These medications function by inhibiting glucose and sodium reabsorption …